Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Effect of BTI320 in Addition to Current Treatment With Metformin and/or Sulfonylureas on Glycemic Control in Subjects With Type 2 Diabetes
Latest Information Update: 04 Nov 2021
At a glance
- Drugs BTI 320 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Boston Therapeutics
- 24 Sep 2020 Status changed from recruiting to completed.
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.
- 07 Sep 2018 New trial record